drugset / Trial / NCT00941343
Benign Prostatic Hyperplasia in Taiwan
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective: * To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: * To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders * To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions * To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) * To assess the onset of action of XATRAL 10mg OD * To assess the peak urinary flow rate * To assess the safety and the tolerability of XATRAL 10mg OD
Timeline
- Start
- 2006-09
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alfuzosin | Small molecule | 10 mg | Oral |